Teva launches new arthritis and skin disease products

Teva has announced the launch of two new products in the UK, expanding its market-leading range of competitively priced generic drugs.

The first of these, diclofenac/misoprostol tablets, are an off-label version of Arthrotec, Pfizer's branded therapy for osteoarthritis and rheumatoid arthritis among patients at high risk of developing stomach ulcers common to nonsteroidal anti-inflammatory drugs.

Meanwhile, the firm has also introduced mometasone furoate cream, which is based on Merck Sharp and Dohme's topical therapy Elocon, for the treatment of skin diseases such as psoriasis and dermatitis.

This new offering will complement Teva's existing mometasone ointment offering.

Kim Innes, commercial director at Teva UK, said: "Last year, we launched 51 products, including 17 day-one launches – our portfolio now comprises over 700 products and is the widest of any UK generics supplier." 

In March 2013, the company added memantine – a generic equivalent of Lundbeck's Alzheimer's disease therapy Ebixa – to its Teva 360 range.